38.07
+1.53(+4.19%)
Currency In USD
| Previous Close | 36.54 |
| Open | 37.08 |
| Day High | 38.14 |
| Day Low | 36.19 |
| 52-Week High | 51.61 |
| 52-Week Low | 31.77 |
| Volume | 397,282 |
| Average Volume | 677,950 |
| Market Cap | 2.41B |
| PE | -14.59 |
| EPS | -2.61 |
| Moving Average 50 Days | 41.91 |
| Moving Average 200 Days | 40.17 |
| Change | 1.53 |
If you invested $1000 in Vera Therapeutics, Inc. (VERA) since IPO date, it would be worth $3,310.43 as of February 05, 2025 at a share price of $38.07. Whereas If you bought $1000 worth of Vera Therapeutics, Inc. (VERA) shares 3 years ago, it would be worth $1,868.92 as of February 05, 2025 at a share price of $38.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2025 9:05 PM GMT
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
GlobeNewswire Inc.
Nov 18, 2024 1:00 PM GMT
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise